Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure

Journal of the American College of Cardiology

Volumn 40, Issue 8, 2002, Pages 1383-1388

  Shyu, Kou G ^a   Cheng, Jun Jack ^a   Kuan, Peiliang ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IOPAMIDOL; SODIUM CHLORIDE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HYDRATION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

ACETYLCYSTEINE; AGED; COMORBIDITY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CREATININE; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; IOPAMIDOL; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0037120963     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02308-2     Document Type: Article

References (32)

1. Vlietstra RE, Nunn CM, Narvarte J, et al. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J 1996;132:1049-50.
2. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
3. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary/artery disease. N Engl J Med 1994;331:489-95.
4. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
5. Korr KS, Reitman A. Renal implications of percutaneous coronary intervention. Semin Nephrol 2001;21:36-46.
6. Taliercio CP, Vlietstra RE, Fisher LD, et al. Risks for renal dysfunction with cardiac angiography. Ann Intern Med 1986;104:501-4.
7. Cigarroa RC, Lange RA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86:649-52.
8. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
9. Weisberg LS, Kurnik PB, Kurink BRC. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994;45:259-65.
10. Erley CM, Duda SH, Schlepckow S, et al. Adensoine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994;45:1425-31.
11. Kapoor A, Sinha N, Sharma RK, et al. Use of dopamine in prevention of contrast induced acute renal failure: a randomized study. Int J Cardiol 1996;53:233-6.
12. Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998;31:674-80.
13. Hans SS, Hans BA, Dhillon R, et al. Effect of dopamine on renal function after arteriography in patients with preexisting renal insufficiency. Am Surg 1998;64:432-6.
14. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med 1995;332:647-55.
15. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen radicals. Am J Physiol 1990;258:F115-20.
16. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
17. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography- related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-8.
18. Levy EM, Viscoli CM, Horowitz RI. The effect of acute renal failure on mortality. JAMA 1996;275:1489-94.
19. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989;320:143-9.
20. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Arch Intern Med 1990;150:1237-42.
21. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542-8.
22. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-9.
23. Mouhayar EN, Tadros G, Akinwande AAO, Campbell B, Blankenship JC, Iliadis EA. Prevention of contrast-induced renal dysfunction with acetylcysteine in patients undergoing coronary angiography (abstr). J Am Coll Cardiol 2002;39 Suppl A:1A.
24. Adamian MG, Moussa I, Mehran R, et al. The role of Mucomyst administration prior to percutaneous intervention on renal function in patients with chronic renal failure (abstr). J Am Coll Cardiol 2002;39 Suppl A:1A.
25. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy. J Am Coll Cardiol 1999;33:403-11.
26. Weinbroum AA, Rudick V, Ben-Abraham R, et al. N-acetyl-L- cysteine for preventing lung reperfusion injury after liver ischemia-reperfusion: a possible dual protective mechanism in a dose-response study. Transplantation 2000;69:853-9.
27. Arstall MA, Yang J, Stafford I, et al. N-acetylcysteine in combination with nitroglycerin and streptokinase for treatment of evolving acute myocardial infarction: safety and biochemical effects. Circulation 1995;92:2855-62.
28. Pollman MJ, JL, Gibbons GH. Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury: influence of redox state and cell phenotype. Circ Res 1999;84:113-21.
29. Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis: a double-blind controlled study. Eur J Respir Dis 1980;61:93-108.
30. Prescott LF, Ballantyne A, Park J, et al. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977;2:432-4.
31. Morgan LR, Holdiness MR, Gillen LE. N-acetylcysteine: its bioavailability and interaction with ifosamide metabolites. Semin Oncol 1983;10:56-61.
32. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents: a new use for an old drug. N Engl J Med 2000;343:210-2.